Sarepta Therapeutics (Brazil) Technical Analysis
| S1RP34 Stock | BRL 31.35 0.72 2.35% |
As of the 2nd of March, Sarepta Therapeutics has the Coefficient Of Variation of (517.09), risk adjusted performance of (0.14), and Variance of 5.11. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Sarepta Therapeutics, as well as the relationship between them.
Sarepta Therapeutics Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Sarepta, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to SareptaSarepta |
Sarepta Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Sarepta Therapeutics Technical Analysis
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Sarepta Therapeutics volatility. High ATR values indicate high volatility, and low values indicate low volatility.
Sarepta Therapeutics Trend Analysis
Use this graph to draw trend lines for Sarepta Therapeutics. You can use it to identify possible trend reversals for Sarepta Therapeutics as well as other signals and approximate when it will take place. Remember, you need at least two touches of the trend line with actual Sarepta Therapeutics price movement. To start drawing, click on the pencil icon on top-right. To remove the trend, use eraser icon.Sarepta Therapeutics Best Fit Change Line
The following chart estimates an ordinary least squares regression model for Sarepta Therapeutics applied against its price change over selected period. The best fit line has a slop of 0.17 , which may suggest that Sarepta Therapeutics market price will keep on failing further. It has 122 observation points and a regression sum of squares at 1046.18, which is the sum of squared deviations for the predicted Sarepta Therapeutics price change compared to its average price change.About Sarepta Therapeutics Technical Analysis
The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of Sarepta Therapeutics on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of Sarepta Therapeutics based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on Sarepta Therapeutics price pattern first instead of the macroeconomic environment surrounding Sarepta Therapeutics. By analyzing Sarepta Therapeutics's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of Sarepta Therapeutics's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to Sarepta Therapeutics specific price patterns or momentum indicators. Please read more on our technical analysis page.
Sarepta Therapeutics March 2, 2025 Technical Indicators
Most technical analysis of Sarepta help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Sarepta from various momentum indicators to cycle indicators. When you analyze Sarepta charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.14) | |||
| Market Risk Adjusted Performance | (2.86) | |||
| Mean Deviation | 1.58 | |||
| Coefficient Of Variation | (517.09) | |||
| Standard Deviation | 2.26 | |||
| Variance | 5.11 | |||
| Information Ratio | (0.19) | |||
| Jensen Alpha | (0.44) | |||
| Total Risk Alpha | (0.38) | |||
| Treynor Ratio | (2.87) | |||
| Maximum Drawdown | 11.5 | |||
| Value At Risk | (5.89) | |||
| Potential Upside | 3.12 | |||
| Skewness | (0.63) | |||
| Kurtosis | 1.55 |
Complementary Tools for Sarepta Stock analysis
When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |